Pharmacy Times

JUNE 9, 2025

These treatments are already in widespread use across health systems, from Mayo Clinic’s 9 active and 5 pending to University of California (UC) San Diego Health’s 12 active and 5 under review. At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline.

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JULY 9, 2025

Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A. Pharmacy Times.

Labelling 65

Labelling FDA Compounding Pharmacies Independent Pharmacies 65

Pharmacy Times

JUNE 26, 2025

In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426). Subscribe Now!

Compounding Pharmacies 65

Compounding Pharmacies Vaccines Immunization Mayo Clinic 65

Pharmacy Times

JULY 14, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer.

FDA 73

FDA Compounding Pharmacies Compounding Immunization 73

Pharmacy Times

JUNE 24, 2025

1 With this approval, belimumab is now accessible for patients and their caregivers at home, rather than needing to travel to a hospital or clinic to receive treatment. This formulation was administered in a clinical setting every 4 weeks for about an hour. Mayo Clinic. McGovern G. Pharmacy Times. February 4, 2025.

FDA 106

FDA Compounding Pharmacies Vaccines Immunization 106

Drug Topics

JUNE 24, 2025

It would be a 1-hour infusion in a hospital or clinic setting every 4 weeks, following an initial loading phase given on days 0, 14, and 28. Mayo Clinic. This approval expanded access to the medication and allowed health care providers to determine if at-home administration is appropriate for the patient. REFERENCES 1.

FDA 509

FDA Immunization Vaccines Mayo Clinic 509

Pharmacy Times

JUNE 19, 2025

1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from Mayo Clinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.

Chemotherapy 73

Chemotherapy Compounding Pharmacies Hospitals Immunization 73

Pharmacy Times

JUNE 15, 2025

Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to Mayo Clinic. Mayo Clinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.

Mayo Clinic 106

Mayo Clinic Compounding Pharmacies Immunization Compounding 106

Drug Topics

JULY 16, 2025

READ MORE: COVID-19 Hospitalizations Disproportionately Impacted Black, Hispanic Children “Resilience is the extent to which we can bounce back from adverse events, cope with stress, or succeed in the face of adversity,” said Cindy Bergeman, PhD, MS, professor of developmental psychology at the University of Notre Dame. Mayo Clinic.

Specialty Pharmacies 316

Specialty Pharmacies Independent Pharmacies Compounding Vaccines 316

Pharmacy Times

JUNE 9, 2025

Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.

Compounding Pharmacies 82

Compounding Pharmacies Immunization Mayo Clinic Compounding 82

Pharmacy Times

JULY 18, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults. EuerkAlert!

Compounding Pharmacies 73

Compounding Pharmacies Compounding Immunization Mayo Clinic 73

Pharmacy Times

JULY 14, 2025

Mayo Clinic. " 1 REFERENCES 1. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation. Accessed July 7, 2025. Boston Scientific. FARAPULSE™ Pulsed Field Ablation System. Accessed July 7, 2025.

Labelling 65

Labelling FDA Compounding Pharmacies Hospitals 65

The Checkup by Singlecare

SEPTEMBER 22, 2023

This year, there are new vaccines to help at-risk populations ward off severe sickness, including that caused by RSV. Here’s what you need to know about the new FDA-approved RSV vaccine. Is there a vaccine for RSV? Not all vaccines work via the same science. Not all vaccines work via the same science. What is RSV?

Vaccines 105

Vaccines Immunization Insurance FDA 105

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 98

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

DECEMBER 15, 2022

Malcolm Macartney is a Medical Adviser for Infectious Diseases and Vaccines at Janssen UK, holding the position since June 2020. Malcolm has dedicated his career to virology and has extensive experience working as a clinical and R&D scientist, researching therapies for viruses, including HIV, HBV, HCV and influenza. Mayo Clinic.

Mayo Clinic 69

Mayo Clinic Hospitals Vaccines 69

The Checkup by Singlecare

NOVEMBER 13, 2023

To help decrease the risk of shingles, Shingrix vaccine is FDA-approved for adults 50 and older. It is a two-vaccine series and significantly decreases the risk of a shingles outbreak. While there is no cure for shingles, it’s important to report it immediately to a healthcare provider to reduce the chances of associated complications.

Mayo Clinic 52

Mayo Clinic Vaccines Chemotherapy Communication 52